Thromboembolic Concerns Raised After Evidence Points to High Risk of Adverse Events Caused by Popular Drugs
Xeljanz and Jakafi
According to AJMC.com, one popular drug frequently prescribed to people suffering from rheumatoid arthritis and another that treats myelofibrosis and polycythemia vera has been linked to life-threatening thromboembolic medical events. The research shows that tofacitinib, widely known by the brand name Xeljanz and ruxolitinib, known by the brand name Jakafi, account for hundreds of cases of Thromboembolic adverse effects as noted in the U.S. Food and Drug Administrations’ Adverse Effect Reporting System (FAERS). The research indicates that Janus kinase inhibitors such as Xeljanz and Jakafi should be further investigated for a causal link between thromboembolic events.
If you or your beloved family member suffered a blood clot or an embolism while taking Xeljanz, Jakafi, or another Janus kinase inhibitor, you could be eligible to receive substantial economic compensation. National plaintiff’s law firm Parker Waichman LLP is accepting clients who suffered a thromboembolic event or whose family member died as a result of a blood clot or embolism while taking a Janus kinase inhibitor.
Parker Waichman LLP’s drug defect attorneys are highly trained and skilled advocates. They have filed lawsuits against some of the largest medical manufacturers in the world on behalf of their clients and won significant monetary damages. Parker Waichman LLP’s drug defect attorneys’ experience investigating potential liability for defective medications, as well as their extensive experience litigating complex cases like strict liability for medical product defects gives their clients the advantage they need to maximize their financial compensation for damages caused by careless pharmaceutical manufacturers.
Parker Waichman LLP’s drug manufacturing defect lawyers’ sole mission is to help their clients find justice for their losses. Currently, Parker Waichman LLP has recovered over $2 billion in damages for their clients. Few, if any, national plaintiff’s law firms can document such an outstanding track record of success. The firm’s resources coupled with stellar advocacy helps provide injured clients and their families the edge they need in their pursuit of justice.
How do you know if you or a family member has a claim?
Parker Waichman LLP’s prescription defect attorneys will review all of the details of your case with you to determine if you have a potential case. New research has shown that many serious medical complications are linked to the class of Janus kinase inhibitors. If you or a loved one experienced one or more of the following severe medical complications while taking a Janus kinase inhibitor, then you could have a claim for substantial damages:
- Pulmonary embolism,
- Pulmonary thrombosis,
- Portal vein thrombosis,
- Deep vein thrombosis, or
- Thrombosis.
Patients who took Janus kinase inhibitors and developed these thromboembolic adverse effects suffered through numerous hospitalizations, near-death experiences, and some people died as a result of the thromboembolic event.
Despite the mounting evidence, the FDA has done virtually nothing to warn physicians and patients about the potentially life-threatening problems they could encounter while taking a Janus kinase inhibitor. Strangely, the FDA has written an opinion about another medicine in the Janus kinase inhibitor class called baricitinib in which the FDA acknowledges that there is a possible link between this class of medications and thromboembolic medical emergencies. Additionally, food and drug regulators in Japan and in the European Union where baricitinib is on the market require the drug to contain stern warnings about the potential side effects of the drug. Notwithstanding, the FDA has not required manufacturers to attach stern warnings to their products about the possibility of suffering from a thromboembolic event which taking the medication.
Call for Your Complimentary Janus Kinase Inhibitor Injury Case Analysis
If you suffered blood clots or embolisms while taking a Janus kinase inhibitor or if one of your family members died as a consequence of taking a Janus kinase inhibitor, then you may be eligible to receive substantial financial compensation. Contact Parker Waichman LLP’s Janus kinase inhibitor injury lawyers today at 1-800-YOUR-LAWYER (1-800-968-7529). Remember that time is limited so call now to learn more about your legal rights and options. For specific information regarding filing a Xeljanz claim, visit our page Xeljanz Thromboembolic Injury and Fatal Lung Clot Lawsuit.
New York | Brooklyn | Queens | Long Island | New Jersey | Florida
Call us at: 1-800-YOURLAWYER (800-968-7529) | Schedule your free consultation
Have you or a loved one suffered severe complications with Janus Kinase inhibitors Xeljanz or Jakafi?
Click To Get A Free Case Review
